AtriCure, Inc.
ATRC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 17.05 | 8.81 | 0.98 | -0.25 |
| FCF Yield | 1.73% | 0.90% | -0.86% | -0.62% |
| EV / EBITDA | 201.10 | 2,073.63 | -253.01 | -154.39 |
| Quality | ||||
| ROIC | 0.12% | -1.19% | -1.16% | -2.74% |
| Gross Margin | 75.47% | 74.54% | 74.93% | 74.53% |
| Cash Conversion Ratio | -100.06 | -3.49 | 1.63 | -0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.83% | 10.99% | 11.18% | 12.09% |
| Free Cash Flow Growth | 108.61% | 205.66% | -49.11% | -154.02% |
| Safety | ||||
| Net Debt / EBITDA | -9.28 | -55.39 | 3.77 | 5.12 |
| Interest Coverage | 0.07 | -4.16 | -4.20 | -10.01 |
| Efficiency | ||||
| Inventory Turnover | 0.42 | 0.45 | 0.41 | 0.42 |
| Cash Conversion Cycle | 257.95 | 175.21 | 190.53 | 186.70 |